Home > Insider Trading > Filing (0001144204-16-107341)

Filing Details

Accession Number:: 0001144204-16-107341
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-07 17:42:47
Reporting Period:: 2016-06-03

Filing Date:: 2016-06-07
Accepted Time:: 2016-06-07 17:42:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619731	Morton Goldberg	C/O Eyegate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA 02452		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-06-03	33,775	$0.65	43,216	No	4	M	Direct
Common Stock	Disposition	2016-06-03	4,650	$3.37	38,566	No	4	S	Direct
Common Stock	Disposition	2016-06-06	5,543	$3.25	33,023	No	4	S	Direct
Common Stock	Disposition	2016-06-07	746	$3.31	32,277	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	14,493	$0.00	14,493	$0.65
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	5,353	$0.00	5,353	$0.65
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	2,276	$0.00	2,276	$0.65
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	3,809	$0.00	3,809	$0.65
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	5,112	$0.00	5,112	$0.65
Common Stock	Stock Option (right to buy)	Disposition	2016-06-03	2,732	$0.00	2,732	$0.65

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2018-09-29	No	4	M	Direct
2020-01-29	No	4	M	Direct
2020-01-29	No	4	M	Direct
2020-06-25	No	4	M	Direct
2021-01-14	No	4	M	Direct
2022-12-23	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The Reporting Person was granted options to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. Each option become exercisable immediately upon grant.
The Reporting Person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on December 23, 2013, with 2.79% of the shares underlying the option vesting monthly thereafter.